Literature DB >> 18194708

Appropriate patient selection in the focal treatment of prostate cancer: the role of transperineal 3-dimensional pathologic mapping of the prostate--a 4-year experience.

Winston E Barzell1, Myron R Melamed.   

Abstract

This study was undertaken to evaluate the usefulness of transperineal mapping biopsy of the prostate as a staging procedure in the appropriate selection of patients for treatment with focal cryoablation. Between October 2001 and January 2006, a total of 80 patients underwent extensive template-guided transperineal pathologic mapping of the prostate (3-DPM), in conjunction with repeat transrectal ultrasound (TRUS)-guided biopsies. Before 3-DPM was performed, the following clinical variables were recorded: age, prostate-specific antigen (PSA), percent free PSA, total prostate volume, transition zone volume, Gleason score, TNM stage, number of positive cores, and maximum percent of positive cores. Results of 3-DPM were compared with those of TRUS-guided biopsies to determine patient suitability for focal cryoablation; this served as the study end point. Of 80 study patients, 43 (54%) were deemed unsuitable for focal cryoablation. When compared with 3-DPM in assessing patient suitability for focal cryoablation repeat TRUS-guided biopsies yielded a false-negative rate of 47%, a sensitivity of 54%, and a negative predictive value of 49%. None of the pre-3-DPM variables correlated significantly with patient suitability for focal ablation. Treatment selected by the 80 study patients included total gland cryoablation (30%), expectant management (23%), radical prostatectomy (18%), focal cryoablation (11%), external irradiation (10%), brachytherapy (6%), and combined external irradiation and brachytherapy (1%); 1% were undecided about treatment selection. In this study, we demonstrated that 3-DPM (1) effectively excluded patients with clinically significant unsuspected cancer outside the area destined to be ablated, (2) appeared to do so more effectively than repeat TRUS-guided biopsies, and (3) was able to precisely locate the site of the cancer to be selectively ablated.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18194708     DOI: 10.1016/j.urology.2007.06.1126

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  58 in total

1.  [MRI navigated stereotactic prostate biopsy: fusion of MRI and real-time transrectal ultrasound images for perineal prostate biopsies].

Authors:  T H Kuru; C Tulea; T Simpfendörfer; V Popeneciu; M Roethke; B A Hadaschik; M Hohenfellner
Journal:  Urologe A       Date:  2012-01       Impact factor: 0.639

2.  Focal therapy: a new paradigm for the treatment of prostate cancer.

Authors:  Basir Tareen; Guilherme Godoy; Samir S Taneja
Journal:  Rev Urol       Date:  2009

3.  Contemporary technique of intraoperative 3-dimensional ultrasonography-guided transperineal prostate cryotherapy.

Authors:  Venu Chalasani; Lori Gardi; Carlos H Martinez; Donal B Downey; Aaron Fenster; Joseph L Chin
Journal:  Can Urol Assoc J       Date:  2009-04       Impact factor: 1.862

4.  Focal therapy for prostate cancer.

Authors:  Peter T Scardino
Journal:  Nat Rev Urol       Date:  2009-04       Impact factor: 14.432

5.  Pathology: the lottery of conventional prostate biopsy.

Authors:  Gerald L Andriole
Journal:  Nat Rev Urol       Date:  2009-04       Impact factor: 14.432

Review 6.  Transperineal biopsy of the prostate--is this the future?

Authors:  Dwayne T S Chang; Benjamin Challacombe; Nathan Lawrentschuk
Journal:  Nat Rev Urol       Date:  2013-09-24       Impact factor: 14.432

7.  The importance of active surveillance, and immediate re-biopsy in low-risk prostate cancer: The largest series from Turkey.

Authors:  Göksel Bayar; Kaya Horasanlı; Hüseyin Acinikli; Orhan Tanrıverdi; Ayhan Dalkılıç; Serdar Arısan
Journal:  Turk J Urol       Date:  2016-09

8.  Management of low-risk prostate cancer.

Authors:  Robert A Gardiner; Freddie C Hamdy
Journal:  World J Urol       Date:  2008-09-19       Impact factor: 4.226

9.  There is no role for focal therapy in prostate cancer.

Authors:  Peter Black
Journal:  Can Urol Assoc J       Date:  2009-08       Impact factor: 1.862

10.  Characterizing indeterminate (Likert-score 3/5) peripheral zone prostate lesions with PSA density, PI-RADS scoring and qualitative descriptors on multiparametric MRI.

Authors:  Mrishta Brizmohun Appayya; Harbir S Sidhu; Nikolaos Dikaios; Edward W Johnston; Lucy Am Simmons; Alex Freeman; Alexander Ps Kirkham; Hashim U Ahmed; Shonit Punwani
Journal:  Br J Radiol       Date:  2017-12-15       Impact factor: 3.039

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.